Physician profile
Mark D Shelnutt
NPI 1508177957
$959.89
in general payments reported to CMS, 2019-2025
16 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.07 · 2020: $126 · 2022: $98.29 · 2023: $205 · 2024: $125 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $142.35 | 2020-2025 | |
| Glaxosmithkline, LLC. | $97.86 | 2019-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $87.33 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $86.33 | 2019-2024 | Breztri, Airsupra |
| Amgen INC. | $86.05 | 2023-2025 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $69.00 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.77 | 2022-2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $60.07 | 2025 | |
| Astellas Pharma US INC | $56.70 | 2019-2024 | Veozah |
| Novo Nordisk INC | $48.23 | 2019-2024 | Ozempic, Rybelsus |
| Dexcom, INC. | $44.90 | 2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $39.40 | 2022-2025 | |
| Allergan, INC. | $29.39 | 2019-2020 | |
| Abbott Laboratories | $16.16 | 2025 | Freestyle Libre |
| Sanofi Pasteur INC. | $13.89 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.46 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shelnutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.